Diabetes and obesity boom will propel Lilly, Novo to front of pharma sales pack by 2030: Evaluate
Fueled by sales of its diabetes and obesity products, Eli Lilly will become the world’s top-seller of prescription drugs by 2030 and will hold the top rung by a wide margin, according to data analytics specialist Evaluate Pharma in its 2030 projection.
